These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 18703743)

  • 21. Targeting T cells to tumor cells using bispecific antibodies.
    Frankel SR; Baeuerle PA
    Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific T-cell engaging antibodies for cancer therapy.
    Baeuerle PA; Reinhardt C
    Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
    Zimmerman Z; Maniar T; Nagorsen D
    Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
    Baeuerle PA; Kufer P; Bargou R
    Curr Opin Mol Ther; 2009 Feb; 11(1):22-30. PubMed ID: 19169956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinatumomab: first global approval.
    Sanford M
    Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
    Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
    Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
    Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
    J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells.
    Otz T; Grosse-Hovest L; Hofmann M; Rammensee HG; Jung G
    Leukemia; 2009 Jan; 23(1):71-7. PubMed ID: 18830257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.
    Trojan A; Schultze JL; Witzens M; Vonderheide RH; Ladetto M; Donovan JW; Gribben JG
    Nat Med; 2000 Jun; 6(6):667-72. PubMed ID: 10835683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.